PharmaCyte Biotech, Inc. PMCB
PharmaCyte Biotech, Inc. (Nasdaq: PMCB) is an oncology drug developer. Its lead program, CypCaps (Cell-in-a-Box encapsulated cells with prodrug), is in Pre-clinical for locally advanced, inoperable, non-metastatic pancreatic cancer (LAPC). Its next catalyst on record is corporate (Nasdaq listing): Nasdaq minimum bid price compliance deadline; reverse split authorized if needed (November 30, 2026).
Upcoming catalysts
- November 30, 2026corporate (Nasdaq listing) — Nasdaq minimum bid price compliance deadline; reverse split authorized if needed
On June 2, 2026, we received a written notice (the "Extension Notice") from Nasdaq advising us that we are eligible for an additional 180-calendar-day compliance period, or until November 30, 2026 (the "Compliance Date"), to regain compliance with the Bid Price Rule.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| CypCaps (Cell-in-a-Box) | locally advanced pancreatic cancer (IND on clinical hold since Oct 2020) | cell therapy | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other pre-clinical oncology companies
- Legend Biotech Corp LEGN
- Veracyte, Inc. VCYT
- Indaptus Therapeutics, Inc. INDP
- SL Science Holding Ltd SLBT
- YD Bio Ltd YDES
- OnKure Therapeutics, Inc. OKUR
- Boundless Bio, Inc. BOLD
- NextCure, Inc. NXTC
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.